Literature DB >> 27518436

Caspase-2 deficiency accelerates chemically induced liver cancer in mice.

S Shalini1, A Nikolic1, C H Wilson1, J Puccini1, N Sladojevic1, J Finnie2, L Dorstyn1, S Kumar1.   

Abstract

Aberrant cell death/survival has a critical role in the development of hepatocellular carcinoma (HCC). Caspase-2, a cell death protease, limits oxidative stress and chromosomal instability. To study its role in reactive oxygen species (ROS) and DNA damage-induced liver cancer, we assessed diethylnitrosamine (DEN)-mediated tumour development in caspase-2-deficient (Casp2(-/-)) mice. Following DEN injection in young animals, tumour development was monitored for 10 months. We found that DEN-treated Casp2(-/-) mice have dramatically elevated tumour burden and accelerated tumour progression with increased incidence of HCC, accompanied by higher oxidative damage and inflammation. Furthermore, following acute DEN injection, liver injury, DNA damage, inflammatory cytokine release and hepatocyte proliferation were enhanced in mice lacking caspase-2. Our study demonstrates for the first time that caspase-2 limits the progression of tumourigenesis induced by an ROS producing and DNA damaging reagent. Our findings suggest that after initial DEN-induced DNA damage, caspase-2 may remove aberrant cells to limit liver damage and disease progression. We propose that Casp2(-/-) mice, which are more susceptible to genomic instability, are limited in their ability to respond to DNA damage and thus carry more damaged cells resulting in accelerated tumourigenesis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27518436      PMCID: PMC5041200          DOI: 10.1038/cdd.2016.81

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  47 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Authors:  A Wree; C D Johnson; J Font-Burgada; A Eguchi; D Povero; M Karin; A E Feldstein
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

3.  SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.

Authors:  Juan L García-Rodríguez; Lucía Barbier-Torres; Sara Fernández-Álvarez; Virginia Gutiérrez-de Juan; María J Monte; Emina Halilbasic; Daniel Herranz; Luis Álvarez; Patricia Aspichueta; Jose J G Marín; Michael Trauner; Jose M Mato; Manuel Serrano; Naiara Beraza; María Luz Martínez-Chantar
Journal:  Hepatology       Date:  2014-03-31       Impact factor: 17.425

Review 4.  Liver cell cancer: insights into the pathogenesis of hepatocellular carcinoma in humans from experimental hepatocarcinogenesis in the rat.

Authors:  E Farber
Journal:  Monogr Pathol       Date:  1987

5.  Deletion of Bid impedes cell proliferation and hepatic carcinogenesis.

Authors:  Li Bai; Hong-Min Ni; Xiaoyun Chen; Daniell DiFrancesca; Xiao-Ming Yin
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

6.  A tumor suppressor function for caspase-2.

Authors:  Lien Ha Ho; Robyn Taylor; Loretta Dorstyn; Dimitrios Cakouros; Philippe Bouillet; Sharad Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-11       Impact factor: 11.205

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

Review 8.  Hepatocellular carcinoma: Review of disease and tumor biomarkers.

Authors:  Jin Un Kim; Mohamed I F Shariff; Mary M E Crossey; Maria Gomez-Romero; Elaine Holmes; I Jane Cox; Haddy K S Fye; Ramou Njie; Simon D Taylor-Robinson
Journal:  World J Hepatol       Date:  2016-04-08

9.  PIDDosome-independent tumor suppression by Caspase-2.

Authors:  C Manzl; L Peintner; G Krumschnabel; F Bock; V Labi; M Drach; A Newbold; R Johnstone; Andreas Villunger
Journal:  Cell Death Differ       Date:  2012-05-18       Impact factor: 15.828

Review 10.  Involvement of DNA damage response pathways in hepatocellular carcinoma.

Authors:  Sheau-Fang Yang; Chien-Wei Chang; Ren-Jie Wei; Yow-Ling Shiue; Shen-Nien Wang; Yao-Tsung Yeh
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

View more
  16 in total

1.  Caspase 2 in mitotic catastrophe: The terminator of aneuploid and tetraploid cells.

Authors:  Ilio Vitale; Gwenola Manic; Maria Castedo; Guido Kroemer
Journal:  Mol Cell Oncol       Date:  2017-03-10

Review 2.  Targeting apoptotic caspases in cancer.

Authors:  Ashley Boice; Lisa Bouchier-Hayes
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

3.  Caspases in metabolic disease and their therapeutic potential.

Authors:  Claire H Wilson; Sharad Kumar
Journal:  Cell Death Differ       Date:  2018-05-09       Impact factor: 15.828

Review 4.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Stuart A Aaronson; John M Abrams; Dieter Adam; Patrizia Agostinis; Emad S Alnemri; Lucia Altucci; Ivano Amelio; David W Andrews; Margherita Annicchiarico-Petruzzelli; Alexey V Antonov; Eli Arama; Eric H Baehrecke; Nickolai A Barlev; Nicolas G Bazan; Francesca Bernassola; Mathieu J M Bertrand; Katiuscia Bianchi; Mikhail V Blagosklonny; Klas Blomgren; Christoph Borner; Patricia Boya; Catherine Brenner; Michelangelo Campanella; Eleonora Candi; Didac Carmona-Gutierrez; Francesco Cecconi; Francis K-M Chan; Navdeep S Chandel; Emily H Cheng; Jerry E Chipuk; John A Cidlowski; Aaron Ciechanover; Gerald M Cohen; Marcus Conrad; Juan R Cubillos-Ruiz; Peter E Czabotar; Vincenzo D'Angiolella; Ted M Dawson; Valina L Dawson; Vincenzo De Laurenzi; Ruggero De Maria; Klaus-Michael Debatin; Ralph J DeBerardinis; Mohanish Deshmukh; Nicola Di Daniele; Francesco Di Virgilio; Vishva M Dixit; Scott J Dixon; Colin S Duckett; Brian D Dynlacht; Wafik S El-Deiry; John W Elrod; Gian Maria Fimia; Simone Fulda; Ana J García-Sáez; Abhishek D Garg; Carmen Garrido; Evripidis Gavathiotis; Pierre Golstein; Eyal Gottlieb; Douglas R Green; Lloyd A Greene; Hinrich Gronemeyer; Atan Gross; Gyorgy Hajnoczky; J Marie Hardwick; Isaac S Harris; Michael O Hengartner; Claudio Hetz; Hidenori Ichijo; Marja Jäättelä; Bertrand Joseph; Philipp J Jost; Philippe P Juin; William J Kaiser; Michael Karin; Thomas Kaufmann; Oliver Kepp; Adi Kimchi; Richard N Kitsis; Daniel J Klionsky; Richard A Knight; Sharad Kumar; Sam W Lee; John J Lemasters; Beth Levine; Andreas Linkermann; Stuart A Lipton; Richard A Lockshin; Carlos López-Otín; Scott W Lowe; Tom Luedde; Enrico Lugli; Marion MacFarlane; Frank Madeo; Michal Malewicz; Walter Malorni; Gwenola Manic; Jean-Christophe Marine; Seamus J Martin; Jean-Claude Martinou; Jan Paul Medema; Patrick Mehlen; Pascal Meier; Sonia Melino; Edward A Miao; Jeffery D Molkentin; Ute M Moll; Cristina Muñoz-Pinedo; Shigekazu Nagata; Gabriel Nuñez; Andrew Oberst; Moshe Oren; Michael Overholtzer; Michele Pagano; Theocharis Panaretakis; Manolis Pasparakis; Josef M Penninger; David M Pereira; Shazib Pervaiz; Marcus E Peter; Mauro Piacentini; Paolo Pinton; Jochen H M Prehn; Hamsa Puthalakath; Gabriel A Rabinovich; Markus Rehm; Rosario Rizzuto; Cecilia M P Rodrigues; David C Rubinsztein; Thomas Rudel; Kevin M Ryan; Emre Sayan; Luca Scorrano; Feng Shao; Yufang Shi; John Silke; Hans-Uwe Simon; Antonella Sistigu; Brent R Stockwell; Andreas Strasser; Gyorgy Szabadkai; Stephen W G Tait; Daolin Tang; Nektarios Tavernarakis; Andrew Thorburn; Yoshihide Tsujimoto; Boris Turk; Tom Vanden Berghe; Peter Vandenabeele; Matthew G Vander Heiden; Andreas Villunger; Herbert W Virgin; Karen H Vousden; Domagoj Vucic; Erwin F Wagner; Henning Walczak; David Wallach; Ying Wang; James A Wells; Will Wood; Junying Yuan; Zahra Zakeri; Boris Zhivotovsky; Laurence Zitvogel; Gerry Melino; Guido Kroemer
Journal:  Cell Death Differ       Date:  2018-01-23       Impact factor: 12.067

5.  Impaired haematopoietic stem cell differentiation and enhanced skewing towards myeloid progenitors in aged caspase-2-deficient mice.

Authors:  Swati Dawar; Nur Hezrin Shahrin; Nikolina Sladojevic; Richard J D'Andrea; Loretta Dorstyn; Devendra K Hiwase; Sharad Kumar
Journal:  Cell Death Dis       Date:  2016-12-01       Impact factor: 8.469

6.  Caspase-2-mediated cell death is required for deleting aneuploid cells.

Authors:  S Dawar; Y Lim; J Puccini; M White; P Thomas; L Bouchier-Hayes; D R Green; L Dorstyn; S Kumar
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

7.  The PIDDosome activates p53 in response to supernumerary centrosomes.

Authors:  Luca L Fava; Fabian Schuler; Valentina Sladky; Manuel D Haschka; Claudia Soratroi; Lisa Eiterer; Egon Demetz; Guenter Weiss; Stephan Geley; Erich A Nigg; Andreas Villunger
Journal:  Genes Dev       Date:  2017-01-01       Impact factor: 11.361

8.  Dimer-specific immunoprecipitation of active caspase-2 identifies TRAF proteins as novel activators.

Authors:  Alexander C Robeson; Kelly R Lindblom; Jeffrey Wojton; Sally Kornbluth; Kenkyo Matsuura
Journal:  EMBO J       Date:  2018-06-06       Impact factor: 11.598

9.  Caspase-2 deficiency enhances whole-body carbohydrate utilisation and prevents high-fat diet-induced obesity.

Authors:  Claire H Wilson; Andrej Nikolic; Stephen J Kentish; Marianne Keller; George Hatzinikolas; Loretta Dorstyn; Amanda J Page; Sharad Kumar
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

10.  p53 accumulation following cytokinesis failure in the absence of caspase-2.

Authors:  Yoon Lim; Dylan De Bellis; Loretta Dorstyn; Sharad Kumar
Journal:  Cell Death Differ       Date:  2018-08-06       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.